Shares of NewLink Genetics Corp. (NASDAQ:NLNK) dropped 1.6% during mid-day trading on Tuesday . The company traded as low as $10.03 and last traded at $10.15, with a volume of 93,302 shares traded. The stock had previously closed at $10.32.

NLNK has been the subject of a number of research analyst reports. Mizuho dropped their price objective on shares of NewLink Genetics Corp. from $52.00 to $20.00 and set a “buy” rating for the company in a report on Tuesday, May 10th. Robert W. Baird reaffirmed an “outperform” rating and set a $23.00 price objective (down from $27.00) on shares of NewLink Genetics Corp. in a report on Tuesday, May 10th. SunTrust Banks Inc. downgraded shares of NewLink Genetics Corp. from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $59.00 to $12.00 in a report on Tuesday, May 10th. Zacks Investment Research cut shares of NewLink Genetics Corp. from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th. Finally, Jefferies Group reiterated a “hold” rating and issued a $10.00 target price on shares of NewLink Genetics Corp. in a research report on Wednesday, May 11th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. NewLink Genetics Corp. has an average rating of “Hold” and an average price target of $23.29.

The stock’s market cap is $297.22 million. The stock’s 50-day moving average price is $10.85 and its 200-day moving average price is $14.51.

NewLink Genetics Corp. (NASDAQ:NLNK) last announced its quarterly earnings data on Friday, July 29th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.77) by $0.35. On average, equities analysts expect that NewLink Genetics Corp. will post ($3.06) EPS for the current fiscal year.

A hedge fund recently raised its stake in NewLink Genetics Corp. stock. Dimensional Fund Advisors LP increased its position in NewLink Genetics Corp. (NASDAQ:NLNK) by 0.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 48,507 shares of the company’s stock after buying an additional 300 shares during the period. Dimensional Fund Advisors LP owned approximately 0.17% of NewLink Genetics Corp. worth $1,765,000 at the end of the most recent reporting period.

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.